Curaleaf Relys on Premium Bid to Win Support from Aurora Shareholders
Curaleaf reiterated its bid for Aurora Cannabis, emphasizing a 45% premium and future growth potential, while criticizing Aurora’s execution, debt strategy, and declining guidance. The offer has not yet been accepted.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day